<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03099408</url>
  </required_header>
  <id_info>
    <org_study_id>2016PUSZH001</org_study_id>
    <nct_id>NCT03099408</nct_id>
  </id_info>
  <brief_title>Oral Metronidazole With Lactobacillus Vaginal Suppositories to Prevent Recurrence of Bacterial Vaginosis</brief_title>
  <official_title>A Pilot Study of Efficacy and Safety of Oral Metronidazole Versus Oral Metronidazole With Lactobacillus Vaginal Suppositories to Prevent the Recurrence of Bacterial Vaginosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University Shenzhen Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking University Shenzhen Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      We are trying to determine if Oral Metronidazole with Lactobacillus Vaginal Suppositories is&#xD;
      better than Oral Metronidazole in Preventing the Recurrence of Bacterial Vaginosis&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Bacterial vaginosis (BV) is the most prevalent cause of symptomatic vaginal discharge in the&#xD;
      U.S. and has been associated with complications including preterm delivery of infants, pelvic&#xD;
      inflammatory disease (PID), urinary tract infections (UTI) and acquisition/transmission of&#xD;
      sexually transmitted diseases (STDs) including human immunodeficiency virus (HIV).&#xD;
&#xD;
      Control of BV has been advocated as a means of decreasing the prevalence of these&#xD;
      complications. However, the etiology of BV remains unknown and the current treatment regimens&#xD;
      are inadequate in terms of initial cure and recurrence rates.&#xD;
&#xD;
      Based on currently national guidelines by using oral metronidazole 400 BID for 7 days, a high&#xD;
      recurrence rate of BV were reported.&#xD;
&#xD;
      We hypothesize that the Oral Metronidazole with Lactobacillus Vaginal Suppositories is better&#xD;
      than Oral Metronidazole in Preventing the Recurrence of Bacterial Vaginosis&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 1, 2017</start_date>
  <completion_date type="Actual">December 30, 2020</completion_date>
  <primary_completion_date type="Actual">December 30, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cure rate of BV</measure>
    <time_frame>4 weeks</time_frame>
    <description>Nugent score</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Recurrence of BV</measure>
    <time_frame>12 weeks</time_frame>
    <description>Nugent score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrence of BV</measure>
    <time_frame>24 weeks</time_frame>
    <description>Nugent score</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">66</enrollment>
  <condition>Bacterial Vaginosis</condition>
  <condition>Recurrence</condition>
  <arm_group>
    <arm_group_label>Metronidazole Oral</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Metronidazole Oral</description>
  </arm_group>
  <arm_group>
    <arm_group_label>&quot;Metronidazole&quot; and &quot;Lactobacillus&quot;</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>&quot;Metronidazole&quot; and &quot;Lactobacillus&quot;</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metronidazole Oral</intervention_name>
    <description>Oral metronidazole 400 mg BID for 7 days at first month.</description>
    <arm_group_label>Metronidazole Oral</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>&quot;Metronidazole&quot; and &quot;Lactobacillus&quot;</intervention_name>
    <description>Oral metronidazole metronidazole 400 mg BID for 7 days at first month and Lactobacillus vaginal suppositories for 10 days at first month,second month and third month.</description>
    <arm_group_label>&quot;Metronidazole&quot; and &quot;Lactobacillus&quot;</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Women be at least 18 years of age&#xD;
&#xD;
          -  Have symptoms of vaginal odor and or/discharge&#xD;
&#xD;
          -  Meet the clinical (Amsel) criteria for BV&#xD;
&#xD;
          -  Willing to participate in research&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Presence of another vaginal infection or STD&#xD;
&#xD;
          -  Allergy to metronidazole&#xD;
&#xD;
          -  Pregnant or nursing&#xD;
&#xD;
          -  Use of oral or intravaginal antibiotics within the past 2 weeks&#xD;
&#xD;
          -  HIV or other chronic disease&#xD;
&#xD;
          -  Inability to keep return appointments&#xD;
&#xD;
          -  Contraindications for Lactobacillus Vaginal Suppositories（those without sexual&#xD;
             history）&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>48 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shangrong Fan, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking University Shenzhen Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Salvatore Giovanni Vitale, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Human Pathology in Adulthood and Childhood, University of Messina (Italy)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dept Obstetrics and Gynecology</name>
      <address>
        <city>Shenzhen</city>
        <state>Guangdong</state>
        <zip>518036</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>March 28, 2017</study_first_submitted>
  <study_first_submitted_qc>March 31, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 4, 2017</study_first_posted>
  <last_update_submitted>January 28, 2021</last_update_submitted>
  <last_update_submitted_qc>January 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking University Shenzhen Hospital</investigator_affiliation>
    <investigator_full_name>Shangrong Fan</investigator_full_name>
    <investigator_title>Profesor</investigator_title>
  </responsible_party>
  <keyword>Recurrence</keyword>
  <keyword>Lactobacillus Vaginal Suppositories</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaginosis, Bacterial</mesh_term>
    <mesh_term>Vaginal Diseases</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metronidazole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

